NASDAQ:NDRA ENDRA Life Sciences Q2 2026 Earnings Report $5.60 -0.27 (-4.60%) Closing price 09/15/2026 03:56 PM EasternExtended Trading$6.02 +0.42 (+7.41%) As of 09/15/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ENDRA Life Sciences EPS ResultsActual EPS-$0.63Consensus EPS -$0.84Beat/MissBeat by +$0.21One Year Ago EPSN/AENDRA Life Sciences Revenue ResultsActual RevenueN/AExpected Revenue$0.10 millionBeat/MissN/AYoY Revenue GrowthN/AENDRA Life Sciences Announcement DetailsQuarterQ2 2026Date8/14/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time7:00AM ETUpcoming EarningsENDRA Life Sciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ENDRA Life Sciences Earnings HeadlinesENDRA Shares Rise 12% As Q2 Loss Swings To Profit; Advances Noble Africa MergerSeptember 4, 2026 | rttnews.comENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 17, 2026 | finance.yahoo.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared. | Stansberry Research (Ad)ASP Isotopes to Host Investor Meetings at Citi’s 2026 Natural Resources ConferenceAugust 5, 2026 | quiverquant.comQASP Isotopes Announces Capital Markets Day in London on September 8, 2026July 28, 2026 | quiverquant.comQENDRA Life Sciences (NDRA) Gets a Buy from AscendiantJuly 25, 2026 | theglobeandmail.comSee More ENDRA Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email. Email Address About ENDRA Life SciencesENDRA Life Sciences (NASDAQ:NDRA), Inc. (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies. ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems. Using patented algorithms and specialized hardware, the system captures thermoacoustic signals generated when tissue is exposed to low-power microwave pulses. These signals enable clinicians to visualize temperature distributions during procedures such as radiofrequency ablation, microwave ablation and high-intensity focused ultrasound. The company collaborates with hospitals, academic research centers and medical device partners to conduct preclinical and clinical studies that validate the performance and utility of TAEUS technology. The company holds a growing portfolio of issued and pending patents across the United States, Europe and Asia, and it is advancing toward broader regulatory clearances and international market entry. ENDRA’s leadership team is led by President and Chief Executive Officer David Kaiss, who brings two decades of experience in medical device development, regulatory affairs and commercialization. Under his direction, the company has expanded its R&D capabilities, strengthened manufacturing partnerships and established key distribution channels to support future product launches.View ENDRA Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks RiskyCould Dave & Buster’s Capitulation Signal the Bottom Is Finally In?Navan's Strong Quarter Meets an AI Spending Reality Check3 Defense Stocks Riding the High-Energy Laser BoomLightPath’s Defense Pivot Could Send Shares Higher3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
